“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer," said Dr. Jackson.
The addition of PARP inhibitors, such as olaparib and niraparib, to the maintenance treatment of patients with recurrent, platinum-sensitive ovarian cancer has led to significant progression-free survival (PFS), according to Amanda L. Jackson, MD. THE PFS benefit with these agents were demonstrated in the phase 2 SOLO-2, NOVA, and ARIEL3 trials, respectively.
“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer. We know that there is a role for PARP maintenance [in these patients], because it seems to increase the time until they recur,” said Jackson. “In the frontline setting, hopefully, [PARP maintenance will] push even more patients into permanent remission. These studies help us see that all our patients benefit from a PARP inhibitor. It's just figuring out what's the best time to give it to them.”
To learn more about the impressive results and findings, visit OncLive.
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More